TECH-MAHINDRA-LTD
15.9.2021 10:02:10 CEST | Business Wire | Press release
Tech Mahindra Ltd ., a leading provider of digital transformation, consulting and business re-engineering services, has today announced a long term partnership with the World’s Best University for Sport , Loughborough University.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005429/en/
Over the last sixty years, Loughborough University has made an outstanding contribution to the world of sport. The university combines exceptional athletes, unrivalled facilities and top coaching with research expertise and active partnerships with major sports leaders and organisations.
The partnership is centred on the collaborative development of sport innovation and sport technology to create new opportunities for research and enterprise. This collaboration aims to include:
- The advancement of diversity and sustainability in sport
- Opportunities to progress sport through 5G, augmented reality (AR) and virtual reality (VR)
- Research into how sport is being played and will be played in the future
- The future development of how sport is being consumed and will be consumed
- Sport innovation acceleration, including the scale up of emerging companies
Jagdish Mitra, Chief Strategy Officer and Head of Growth, Tech Mahindra, says:
“We are excited to partner with Loughborough University to build the sports ecosystem of the future. This collaboration between Tech Mahindra a global digital transformation company and the world’s leading sports university will focus on filling technology and domain related innovation within the industry, so we can tap into the full potential of sports which will leverage technology at the core for performance and experience .”
Professor Chris Linton Acting President and Vice Chancellor of Loughborough University said:
“The partnership with Tech Mahindra enables us to strategically build on our established strengths in sport and technology. It also opens up opportunities for colleagues working across a broad spectrum of disciplines, right across the University community. I’m particularly pleased that research, teaching and enterprise activities are all planned. This integrated approach will, I’m sure, deliver enduring value to both parties and I’m excited to see what develops from this pioneering partnership.”
Manish Upadhyay, Head Sports Technology Vertical, Tech Mahindra, added:
“Our collaboration with Loughborough University will enable the sports industry to benefit from both academic and technological advancements. In line with TechM NXT.NOW, this partnership demonstrates our commitment towards transforming how a game is played, how fans are engaged and how next generation of athletes are trained.”
The UK Minister for Investment, Gerry Grimstone, added:
“Our world-leading universities are just one reason why the UK is such an attractive global investment destination. This is a great initiative between Loughborough University – who lead the way in research and development in sport, and Indian tech giant and major investor Tech Mahindra. This collaboration builds on the growing UK-India trade and investment relationship and puts us at the forefront of sports technology.”
“At our Global Investment Summit later this year I hope to see more partnerships like this to drive innovation and growth across the UK.”
As part of its TechM NXT.NOW framework, which aims to enhance ‘Human Centric Experience’, Tech Mahindra has a deep focus on leveraging cutting-edge technologies to deliver enhanced experience and enable digital transformation to meet the evolving needs of the customer.
Connect with us on www.techmahindra.com
Our Social Media Channels
Facebook: https://www.facebook.com/TechMahindra
Twitter: https://twitter.com/Tech_Mahindra
LinkedIn: https://www.linkedin.com/company/tech-mahindra/
YouTube: https://www.youtube.com/user/techmahindra09
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005429/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom